[P2-30] Survey for Ribavirin Therapy for Subacute Sclerosing Encephalitis in Japan
[Introduction] Subacute sclerosing encephalitis (SSPE) is intractable and its prognosis is so bad. Though interferon is known as medicine for SSPE, its effect is limited, and we have felt that therapy for SSPE has not been established yet. We used ribavirin for SSPE patients and some of them had effectiveness. And ribavirin has become to be used for SSPE patients also in other hospitals in Japan. Then we carried out survey for ribavirin therapy for SSPE in Japan.
[Methodology] We send questionnaires to the hospital where SSPE patients had been performed ribavirin therapy. And we asked with informed consent that stage at diagnosis, stage at the starting of ribavirin therapy, stage at present, change in neurologic disability index (NDI), adverse reactions and so on.
[Results] Patients are 12 males and 13 females. Average age of onset is 8.69 years old. For the staging of Jabbour, 3 patients are at the first, 20 at the second and 1 at the third in the begging of the therapy. When we consider that it is improved to decrease over 2 scores of NDI, it is worse to increase over 2 scores and others are unchanged, improved patients are 4, worse are eleven, and unchanged are three. We find drowsiness for 14 patients, fever for 9 patients, lip swelling for 8 patients, general fatigue for 6 patients, liver dysfunction for 5 patients and bacterial meningitis for 5 patients for adverse reactions.
[Conclusions] We decide that Ribavirin therapy for SSPE has some effectiveness.
[Methodology] We send questionnaires to the hospital where SSPE patients had been performed ribavirin therapy. And we asked with informed consent that stage at diagnosis, stage at the starting of ribavirin therapy, stage at present, change in neurologic disability index (NDI), adverse reactions and so on.
[Results] Patients are 12 males and 13 females. Average age of onset is 8.69 years old. For the staging of Jabbour, 3 patients are at the first, 20 at the second and 1 at the third in the begging of the therapy. When we consider that it is improved to decrease over 2 scores of NDI, it is worse to increase over 2 scores and others are unchanged, improved patients are 4, worse are eleven, and unchanged are three. We find drowsiness for 14 patients, fever for 9 patients, lip swelling for 8 patients, general fatigue for 6 patients, liver dysfunction for 5 patients and bacterial meningitis for 5 patients for adverse reactions.
[Conclusions] We decide that Ribavirin therapy for SSPE has some effectiveness.